COL – Morgans rates the stock as Add
The broker maintains its Add rating and increases its target to $20.65 from $19.70.
Read MoreThe broker maintains its Add rating and increases its target to $20.65 from $19.70.
Read MoreTarget price rises to $6.30 from $6.20. Neutral rating retained.
Read MoreThe broker maintains its $80 target price. The Hold rating is unchanged.
Read MoreNeutral maintained. Target rises to $18.81 from $18.32.
Read MoreThe broker lowers its target price to $17.90 from $19.10. Hold.
Read MoreBuy rating retained. Target price rises to $7.90 from $6.73.
Read MoreThe broker assesses the recent sell-off opens up some value and upgrades to Outperform from Neutral. Targets raised to $13.20 from $13.00.
Read MoreNational Australia Bank is now Morgans preferred big four bank exposure and the target price rises to $34 from $30.50. Hold.
Read MoreUnderperform maintained. Target is raised to $1.58 from $1.55.
Read MoreThe broker lowers its target price to $6.00 from $6.30. Buy rating retained.
Read MoreThe company has signalled a seasonally lower profit is expected in the Americas in the June half. Neutral maintained. Target is $3.75.
Read MoreOutperform rating and $6 target unchanged.
Read MoreThe broker lowers its 2023 and 2024 EPS estimates due to lower expected production. The price target falls to $32.20 from $32.90. Neutral.
Read MoreHold rating is maintained. The target is reduced to $18.25 from $20.10.
Read MoreThe broker retains its Neutral rating and $17.25 target price.
Read MoreCredit Suisse retains a Neutral rating. Target is steady at $5.40.
Read MoreNeutral retained, target falls to $6.60 from $6.70.
Read MoreThe Outperform rating is retained and the target price decreases to $2.00 from $2.30.
Read MoreMorgans lowers its target price to $10.65 from $14.50 and maintains its Hold rating.
Read MoreTarget price rises to $5.60 from $4.70. Outperform rating retained.
Read MoreThe Hold rating and $6.41 price target are maintained.
Read MoreThe Outperform rating is retained and the target price decreases to $32.60 from $33.50.
Read MoreThe Outperform rating is retained and the target price decreases to $13.00 from $13.25.
Read MoreThe broker resumes coverage with an Outperform rating and a target price of $1.53.
Read MoreThe Add rating and $11 target price are unchanged.
Read MoreThe Buy rating and target price of $16.00 are retained.
Read MoreOutperform rating, $2.94 target price and earnings forecasts are retained.
Read MoreThe broker retains its Outperform rating and $2.57 target price.
Read MoreThe target price rises to $1.88 from $1.81. Add.
Read MoreTarget price eases -5% to 1.90. Neutral rating retained.
Read MoreMorgans initiates coverage of commercial stage drug development company Pharmaxis with a Speculative Buy rating and $0.58 target price.
Read MoreThe broker maintains its Add rating, while the target edges down to $0.51 from $0.54.
Read MoreThe Neutral rating is maintained on a full valuation, and the broker prefers Santos ((STO)) in the sector. The target falls by -5% to $32.90 on reduced values for the Sangomar and Trion oil fields.
Read MoreThe Outperform rating and target price of $61.00 are retained.
Read MoreThe broker retains its Neutral rating and $4.65 target price.
Read MoreThe Neutral rating is maintained, as the broker feels the current company valuation is elevated. The target of $46 is maintained.
Read MoreThe target rises to $5.20 from $3.72. Add.
Read MoreWith no changes to earnings forecasts or the $2.94 target price, the broker retains its Outperform rating.
Read MoreThe broker reinitiates with a Buy rating and a target price of $44.00.
Read MoreThe broker marginally lowers its EPS forecasts and the target price edges up to $73.05 from $72.94. The Reduce rating is retained.
Read More